AgomAb Therapeutics (NASDAQ:AGMB) Sees Strong Trading Volume – Here’s What Happened

AgomAb Therapeutics NV (NASDAQ:AGMB) saw unusually-strong trading volume on Thursday . Approximately 179,998 shares changed hands during mid-day trading, an increase of 37% from the previous session’s volume of 131,503 shares.The stock last traded at $14.1140 and had previously closed at $13.66.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the stock. HC Wainwright began coverage on shares of AgomAb Therapeutics in a research note on Monday, June 22nd. They issued a “buy” rating and a $35.00 price target for the company. Piper Sandler initiated coverage on shares of AgomAb Therapeutics in a research report on Tuesday, August 25th. They set an “overweight” rating and a $60.00 price objective on the stock. B. Riley Financial started coverage on shares of AgomAb Therapeutics in a report on Thursday, July 23rd. They issued a “buy” rating and a $34.00 target price on the stock. Wall Street Zen lowered shares of AgomAb Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. Finally, Cantor Fitzgerald started coverage on AgomAb Therapeutics in a report on Wednesday, August 19th. They set an “overweight” rating on the stock. Seven investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $37.50.

AgomAb Therapeutics Trading Up 6.0%

The company has a fifty day moving average of $13.28.

AgomAb Therapeutics (NASDAQ:AGMB) last announced its earnings results on Thursday, August 6th. The company reported ($0.46) EPS for the quarter. On average, analysts anticipate that AgomAb Therapeutics NV will post -1.76 earnings per share for the current fiscal year.

AgomAb Therapeutics Company Profile

AgomAb Therapeutics (NASDAQ: AGMB) is a biotechnology company focused on the discovery and development of monoclonal antibody therapeutics. The company’s name and stated strategy center on the creation of agonist antibodies designed to modulate specific receptor pathways, with the aim of providing disease-modifying treatments where conventional approaches have been limited. AgomAb’s work spans early-stage discovery through translational development and regulatory-directed studies.

AgomAb’s activities include antibody engineering, target validation, and progression of programs through preclinical and, when applicable, clinical development milestones.